NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy.
Wang H, Xia L, Yao CC, Dong H, Yang Y, Li C, Ji WX, Sun RM, Duan HQ, Mengzhou W, Xia WM, Wang SJ, Ji P, Li Z, Jiao L, Wang Y, Lu S.
Wang H, et al. Among authors: sun rm.
Cancer Sci. 2022 Mar;113(3):838-851. doi: 10.1111/cas.15243. Epub 2022 Jan 19.
Cancer Sci. 2022.
PMID: 34927309
Free PMC article.